Download PDF
Am J Perinatol 2022; 39(13): 1441-1448
DOI: 10.1055/s-0040-1722653
Original Article

Effects of Inhaled Iloprost for the Management of Persistent Pulmonary Hypertension of the Newborn

Sourabh Verma 
1   Division of Neonatology, Department of Pediatrics, NYU Grossman School of Medicine, New York, New York
,
Rishi Lumba
1   Division of Neonatology, Department of Pediatrics, NYU Grossman School of Medicine, New York, New York
,
Sadaf H. Kazmi
1   Division of Neonatology, Department of Pediatrics, NYU Grossman School of Medicine, New York, New York
,
Michelle J. Vaz
1   Division of Neonatology, Department of Pediatrics, NYU Grossman School of Medicine, New York, New York
,
Shrawani Soorneela Prakash
1   Division of Neonatology, Department of Pediatrics, NYU Grossman School of Medicine, New York, New York
,
Sean M. Bailey
1   Division of Neonatology, Department of Pediatrics, NYU Grossman School of Medicine, New York, New York
,
Pradeep V. Mally
1   Division of Neonatology, Department of Pediatrics, NYU Grossman School of Medicine, New York, New York
,
Tara M. Randis
2   Division of Neonatology, Departments of Pediatrics and Molecular Medicine, University of South Florida, Tampa, Florida
› Author Affiliations Funding None.
› Further Information
    Permissions and Reprints

Abstract

Objective The study aimed to evaluate the effects of inhaled iloprost on oxygenation indices in neonates with persistent pulmonary hypertension of the newborn (PPHN).

Study Design We conducted a retrospective chart review of 30 patients with PPHN from January 2014 to November 2018, who did not respond to inhaled nitric oxide (iNO) alone and received inhaled iloprost. Twenty-two patients met the inclusion criteria and eight patients were excluded from the study (complex cardiac disease and extreme prematurity). Patients were categorized as responders or nonresponders (patients who required extracorporeal membrane oxygenation or died). Oxygenation index, mean airway pressure (MAP), and arterial partial pressure of oxygen (PaO2) were recorded.

Results Among a total of 22 patients who were included in the study, 10 were classified as nonresponders as they required either extracorporeal membrane oxygenation or died. Gestational age and gender did not differ between responders and nonresponders. The median PaO2 was lower (37 vs. 42 mm Hg; p < 0.05) and median MAP was higher (20 vs. 17 cm H2O; p < 0.02) in nonresponders compared with responders just prior to initiating iloprost. Iloprost responders had a significant increase in median PaO2 and decrease in median oxygenation index in the 24 hours after initiating treatment (p < 0.05), with no significant change in required mean airway pressure over that same period. There was no change in vasopressor use or clinically significant worsening of platelets count, liver, and kidney functions after initiating iloprost.

Conclusion Inhaled iloprost is well tolerated and seems to have beneficial effects in improving oxygenation indices in neonates with PPHN who do not respond to iNO. There is a need of well-designed prospective trials to further ascertain the benefits of using inhaled iloprost as an adjunct treatment in neonates with PPHN who do not respond to iNO alone.

Key Points

  • Inhaled iloprost seems to have beneficial effects in improving oxygenation indices in PPHN.

  • Inhaled iloprost is generally well tolerated in newborns with PPHN.

  • There is a need for prospective randomized controlled trials to further ascertain the benefits of using inhaled iloprost.

Keywords

persistent pulmonary hypertension of the newborn - iloprost - nitric oxide - newborn


Publication History

Received: 06 May 2020

Accepted: 11 December 2020

Article published online:
21 January 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Konduri GG, Vohr B, Robertson C. et al; Neonatal Inhaled Nitric Oxide Study Group. Early inhaled nitric oxide therapy for term and near-term newborn infants with hypoxic respiratory failure: neurodevelopmental follow-up. J Pediatr 2007; 150 (03) 235-240 , 240.e1
    CrossrefPubMedGoogle Scholar
  • 2 Morel AA, Shreck E, Mally PV, Kim Y, Bailey SM, Wachtel EV. Clinical characteristics and factors associated with term and late preterm infants that do not respond to inhaled nitric oxide (iNO). J Perinat Med 2016; 44 (06) 663-668
    CrossrefPubMedGoogle Scholar
  • 3 Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med 1997; 336 (09) 597-604
    CrossrefPubMedGoogle Scholar
  • 4 Hintz SR, Van Meurs KP, Perritt R. et al; NICHD Neonatal Research Network. Neurodevelopmental outcomes of premature infants with severe respiratory failure enrolled in a randomized controlled trial of inhaled nitric oxide. J Pediatr 2007; 151 (01) 16-22 , 22.e1–22.e3
    CrossrefPubMedGoogle Scholar
  • 5 Steurer MA, Jelliffe-Pawlowski LL, Baer RJ, Partridge JC, Rogers EE, Keller RL. Persistent pulmonary hypertension of the newborn in late preterm and term infants in california. Pediatrics 2017; 139 (01) e20161165
    CrossrefPubMedGoogle Scholar
  • 6 Ahmad KA, Banales J, Henderson CL, Ramos SE, Brandt KM, Powers GC. Intravenous epoprostenol improves oxygenation index in patients with persistent pulmonary hypertension of the newborn refractory to nitric oxide. J Perinatol 2018; 38 (09) 1212-1219
    CrossrefPubMedGoogle Scholar
  • 7 Kahveci H, Yilmaz O, Avsar UZ. et al. Oral sildenafil and inhaled iloprost in the treatment of pulmonary hypertension of the newborn. Pediatr Pulmonol 2014; 49 (12) 1205-1213
    CrossrefPubMedGoogle Scholar
  • 8 Ehlen M, Wiebe B. Iloprost in persistent pulmonary hypertension of the newborn. Cardiol Young 2003; 13 (04) 361-363
    CrossrefPubMedGoogle Scholar
  • 9 Kelly LE, Ohlsson A, Shah PS. Sildenafil for pulmonary hypertension in neonates. Cochrane Database Syst Rev 2017; 8: CD005494
    PubMedGoogle Scholar
  • 10 Bassler D, Choong K, McNamara P, Kirpalani H. Neonatal persistent pulmonary hypertension treated with milrinone: four case reports. Biol Neonate 2006; 89 (01) 1-5
    CrossrefPubMedGoogle Scholar
  • 11 McNamara PJ, Laique F, Muang-In S, Whyte HE. Milrinone improves oxygenation in neonates with severe persistent pulmonary hypertension of the newborn. J Crit Care 2006; 21 (02) 217-222
    CrossrefPubMedGoogle Scholar
  • 12 Sood BG, Keszler M, Garg M. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Inhaled PGE1 in neonates with hypoxemic respiratory failure: two pilot feasibility randomized clinical trials. Trials 2014; 15: 486
    CrossrefPubMedGoogle Scholar
  • 13 Mohamed WA, Ismail M. A randomized, double-blind, placebo-controlled, prospective study of bosentan for the treatment of persistent pulmonary hypertension of the newborn. J Perinatol 2012; 32 (08) 608-613
    CrossrefPubMedGoogle Scholar
  • 14 Steinhorn RH, Fineman J, Kusic-Pajic A. et al; FUTURE-4 study investigators. Bosentan as adjunctive therapy for persistent pulmonary hypertension of the newborn: results of the randomized multicenter placebo-controlled exploratory trial. J Pediatr 2016; 177: 90-96.e3
    CrossrefPubMedGoogle Scholar
  • 15 Kinsella JP, Walsh WF, Bose CL. et al. Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trial. Lancet 1999; 354 (9184): 1061-1065
    CrossrefPubMedGoogle Scholar
  • 16 Davidson D, Barefield ES, Kattwinkel J. et al; The I-NO/PPHN Study Group. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. Pediatrics 1998; 101 (3 Pt 1): 325-334
    CrossrefPubMedGoogle Scholar
  • 17 Hamon I, Gauthier-Moulinier H, Grelet-Dessioux E, Storme L, Fresson J, Hascoet JM. Methaemoglobinaemia risk factors with inhaled nitric oxide therapy in newborn infants. Acta Paediatr 2010; 99 (10) 1467-1473
    CrossrefPubMedGoogle Scholar
  • 18 Sharma V, Berkelhamer S, Lakshminrusimha S. Persistent pulmonary hypertension of the newborn. Matern Health Neonatol Perinatol 2015; 1: 14
    CrossrefPubMedGoogle Scholar
  • 19 Black SM, Heidersbach RS, McMullan DM, Bekker JM, Johengen MJ, Fineman JR. Inhaled nitric oxide inhibits NOS activity in lambs: potential mechanism for rebound pulmonary hypertension. Am J Physiol 1999; 277 (05) H1849-H1856
    PubMedGoogle Scholar
  • 20 Sokol GM, Fineberg NS, Wright LL, Ehrenkranz RA. Changes in arterial oxygen tension when weaning neonates from inhaled nitric oxide. Pediatr Pulmonol 2001; 32 (01) 14-19
    CrossrefPubMedGoogle Scholar
  • 21 Chotigeat U, Champrasert M, Khorana M, Sangtaweesin V, Kanjanapattanakul W. Iloprost inhalation for the treatment of severe persistent pulmonary hypertension of the newborn, experience at QSNICH. J Med Assoc Thai 2014; 97 (Suppl. 06) S89-S94
    PubMedGoogle Scholar
  • 22 De Luca D, Zecca E, Piastra M, Romagnoli C. Iloprost as ‘rescue’ therapy for pulmonary hypertension of the neonate. Paediatr Anaesth 2007; 17 (04) 394-395
    CrossrefPubMedGoogle Scholar
  • 23 Gupta M, Guertin S, Martin S, Omar S. Inhaled prostacyclin and high-frequency oscillatory ventilation in a premature infant with respiratory syncytial virus-associated respiratory failure. Pediatrics 2012; 130 (02) e442-e445
    CrossrefPubMedGoogle Scholar
  • 24 Moreno-Galdó A, Torrent-Vernetta A, de Mir Messa I. et al. Use of inhaled iloprost in children with pulmonary hypertension. Pediatr Pulmonol 2015; 50 (04) 370-379
    CrossrefPubMedGoogle Scholar
  • 25 Piastra M, De Luca D, De Carolis MP. et al. Nebulized iloprost and noninvasive respiratory support for impending hypoxaemic respiratory failure in formerly preterm infants: a case series. Pediatr Pulmonol 2012; 47 (08) 757-762
    CrossrefPubMedGoogle Scholar
  • 26 Vorhies EE, Caruthers RL, Rosenberg H, Yu S, Gajarski RJ. Use of inhaled iloprost for the management of postoperative pulmonary hypertension in congenital heart surgery patients: review of a transition protocol. Pediatr Cardiol 2014; 35 (08) 1337-1343
    CrossrefPubMedGoogle Scholar
  • 27 Xu Z, Zhu L, Liu X, Gong X, Gattrell W, Liu J. Iloprost for children with pulmonary hypertension after surgery to correct congenital heart disease. Pediatr Pulmonol 2015; 50 (06) 588-595
    CrossrefPubMedGoogle Scholar
  • 28 Yilmaz O, Kahveci H, Zeybek C, Ciftel M, Kilic O. Inhaled iloprost in preterm infants with severe respiratory distress syndrome and pulmonary hypertension. Am J Perinatol 2014; 31 (04) 321-326
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Eifinger F, Sreeram N, Mehler K, Huenseler C, Kribs A, Roth B. Aerosolized iloprost in the treatment of pulmonary hypertension in extremely preterm infants: a pilot study. Klin Padiatr 2008; 220 (02) 66-69
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Avila-Alvarez A, Bravo-Laguna MC, Bronte LD, Del Cerro MJ. Inhaled iloprost as a rescue therapy for transposition of the great arteries with persistent pulmonary hypertension of the newborn. Pediatr Cardiol 2013; 34 (08) 2027-2029
    CrossrefPubMedGoogle Scholar
  • 31 Kirbas A, Yalcin Y, Tanrikulu N, Gürer O, Isik O. Comparison of inhaled nitric oxide and aerosolized iloprost in pulmonary hypertension in children with congenital heart surgery. Cardiol J 2012; 19 (04) 387-394
    CrossrefPubMedGoogle Scholar
  • 32 Konduri GG, Sokol GM, Van Meurs KP. et al. Impact of early surfactant and inhaled nitric oxide therapies on outcomes in term/late preterm neonates with moderate hypoxic respiratory failure. J Perinatol 2013; 33 (12) 944-949
    CrossrefPubMedGoogle Scholar
  • 33 Ewert R, Schäper C, Halank M, Gläser S, Opitz CF. Inhalative iloprost - pharmacology and clinical application. Expert Opin Pharmacother 2009; 10 (13) 2195-2207
    CrossrefPubMedGoogle Scholar
  • 34 Tissot C, Beghetti M. Review of inhaled iloprost for the control of pulmonary artery hypertension in children. Vasc Health Risk Manag 2009; 5 (01) 325-331
    PubMedGoogle Scholar